Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

David Feltl, Petr Arenberger, vaccination, COVID-19, coronavirus

Director of the General University Hospital David Feltl, left, receives vaccine against COVID-19 at the General University Hospital in Prague, Czech Republic, December 27, 2020. At right is director of the University Hospital Kralovske Vinohrady Petr Arenberger. (CTK Photo/Ondrej Deml)

E

Robert Markovic, David Feltl

The General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (left), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. On the right side is seen director of the hospital David Feltl. (CTK Photo/Michal Krumphanzl)

E

Martin Balik, David Feltl

The General Teaching Hospital in Prague (VFN) completed the treatment of a COVID-19 patient, 53, with the Remdesivir experimental drug, the only patient treated with the drug in the Czech Republic so far, the VFN Anaesthesiology Clinic deputy head Martin Balik, left, and VFN director David Feltl reported today, on Friday, April 3, 2020, in Prague, Czech Republic. (CTK Photo/Katerina Sulova)

E

Martin Balik, David Feltl

The General Teaching Hospital in Prague (VFN) completed the treatment of a COVID-19 patient, 53, with the Remdesivir experimental drug, the only patient treated with the drug in the Czech Republic so far, the VFN Anaesthesiology Clinic deputy head Martin Balik, left, and VFN director David Feltl reported today, on Friday, April 3, 2020, in Prague, Czech Republic. (CTK Photo/Katerina Sulova)

E

Martin Balik, David Feltl

The General Teaching Hospital in Prague (VFN) completed the treatment of a COVID-19 patient, 53, with the Remdesivir experimental drug, the only patient treated with the drug in the Czech Republic so far, the VFN Anaesthesiology Clinic deputy head Martin Balik, left, and VFN director David Feltl reported today, on Friday, April 3, 2020, in Prague, Czech Republic. (CTK Photo/Katerina Sulova)

E

Martin Balik, David Feltl

The General Teaching Hospital in Prague (VFN) completed the treatment of a COVID-19 patient, 53, with the Remdesivir experimental drug, the only patient treated with the drug in the Czech Republic so far, the VFN Anaesthesiology Clinic deputy head Martin Balik, left, and VFN director David Feltl reported today, on Friday, April 3, 2020, in Prague, Czech Republic. (CTK Photo/Katerina Sulova)

E

Martin Balik, David Feltl

Doctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)

E

Martin Balik, David Feltl

Doctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)

E

David Feltl

Director of the General Teaching Hospital in Prague David Feltl speaks during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)

E

Martin Balik, David Feltl

Doctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)

E

Martin Balik, David Feltl

Doctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)

E

Martin Balik, David Feltl

Doctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)

E

David Feltl

Director of the General Teaching Hospital in Prague David Feltl speaks during a press conference on coronavirus treatment, on March 24, 2020, in Prague, Czech Republic. The hospital received the remdesivir novel antiviral drug and it started administering it to a patient seriously ill with COVID-19. (CTK Photo/Ondrej Deml)

E

Martin Balik, David Feltl

Doctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 24, 2020, in Prague, Czech Republic. The hospital received the remdesivir novel antiviral drug and it started administering it to a patient seriously ill with COVID-19. (CTK Photo/Ondrej Deml)